Wednesday, July 8, 2026

pharma · Retinitis Pigmentosa · Dry Eye Disease · KPRX

KIORA PHARMACEUTICALS

Kiora Pharmaceuticals is a pharma organization headquartered in Encinitas, USA. It trades on NYSE under ticker KPRX. Primary therapeutic focus areas include Retinitis Pigmentosa, Dry Eye Disease, Macular Edema, Persisten

Encinitas, USA HQ
2013 Founded
18 Employees
Public company Type
KPRX · NYSE Ticker
Company details
Status
Public
HQ
Encinitas, USA
Founded
2013
Employees
18
Programs
5
Drugs
4
Patents
4
Clinical program

KIO-104

Phase 2 · small molecule · Macular Edema

KIO-104 for Macular Edema is a Phase 2 program (small_molecule) at KIORA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

← All KIORA PHARMACEUTICALS INC projects Phase 2 small molecule active

Internal code KIO-104-2100

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
KIORA PHARMACEUTICALS INC
Phase
Phase 2
Modality
small_molecule
Indication
Macular Edema
Status
active
Trials
1